Primary intrathoracic malignant neurogenic tumor: report of three cases and comparison with benign neurogenic tumors resected at our institution
© Kawaguchi et al.; licensee Springer. 2015
Received: 1 October 2014
Accepted: 25 December 2014
Published: 28 January 2015
We present three patients with intrathoracic malignant neurogenic tumor. Two lesions showed no sign of invasion into adjacent structures, while the third lesion extended to the intraspinal canal with vertebral involvement. Although all three lesions were completely excised, each patient relapsed within 1 year of the initial treatment. One patient with local recurrence underwent radiation therapy, but the recurrent tumor continued to progress. Chemotherapy was subsequently performed. Two patients with distant metastases also received chemotherapy. Because there is no effective chemotherapeutic regimen for intrathoracic malignant neurogenic tumor, all three patients received high-dose chemotherapy followed by hematopoietic stem cell transplantation. Although the relapsed lesions temporarily regressed after treatment, all three patients showed disease recrudescence and ultimately died of their disease. A comparison of the intrathoracic malignant neurogenic tumors and the benign neurogenic tumors resected at our institution revealed no meaningful differences distinguishing malignant from benign neurogenic tumors prior to surgery.
Neurogenic tumor is a common intrathoracic neoplasm, representing approximately 20% of all adult and 35% of all pediatric mediastinal neoplasms . Among these cases, malignant neurogenic tumor (MNT) of the thorax is rare. Although its overall incidence remains unclear, it likely accounts for less than 1% to 2% of mediastinal neurogenic tumors . In cases of MNT, radical surgical resection is necessary and is a positive prognostic factor; however, the overall survival is poor because of local and distant relapses. The utility of adjuvant chemotherapy or radiotherapy is unclear [1-6].
We report three cases of intrathoracic MNT treated with surgery. Additionally, we present a comparison of the clinical characteristics and outcomes of these patients and those of patients with benign neurogenic tumors (BNTs) resected at our institution.
The patient received postoperative radiotherapy as an adjuvant treatment, but it was discontinued halfway through when multiple bone metastases were identified. Subsequently, chemotherapy consisting of cisplatin (25 mg/m2 on days 1 to 5), cyclophosphamide (1,200 mg/m2 on days 1 and 2), vincristine (1.5 mg/m2 on day 1), and pirarubicin-doxorubicin (40 mg/m2 on day 3) was administered. However, progressive disease was demonstrated after 3 cycles of this regimen. Next, unrelated cord blood stem cell transplantation was carried out after a myeloablative conditioning regimen (etoposide: 500 mg/m2 on day −7; thiotepa: 180 mg/m2 on days −7, −6, and −5; total body irradiation: 2 Gy × 2 on days −3, −2, and −1). After this treatment, the bone metastases had regressed, and the patient was stable for approximately 1 year. Multiple bone metastases relapsed 18 months after the operation. High-dose chemotherapy comprising flutamide (30 mg/m2 on days −6, −5, and −4) and melpharan (100 mg/m2 on days −3 and −2) was performed followed by autologous peripheral blood stem cell transplantation (auto-PBSCT). Unfortunately, the treatment produced minimal response, and the patient died 24 months after surgery.
The patient received postoperative radiotherapy as an adjuvant treatment (50 Gy). Multiple bone and lung metastases were revealed 14 months postoperatively. High-dose chemotherapy comprising carboplatin (400 mg/m2 on days −7, −6, −5, and −4), etoposide (15 mg/kg on days −5 and −4), and melpharan (90 mg/m2 on days −3 and −2) was performed followed by auto-PBSCT. After the treatment, the metastases regressed, and the patient was stable for 9 months. Lung metastases relapsed 25 months after the operation. Chemotherapy consisting of doxorubicin (20 mg/m2 on days 1 to 3) and ifosfamide (2 g/m2 on days 1 to 3) was administered. The regimen achieved a sustained partial response, and 5 cycles were performed, which reached the maximum dosage limit for doxorubicin. Progressive disease was noted 36 months postoperatively. Chemotherapy comprising dacarbazine (250 mg/m2 on day 1) and ifosfamide (2 g/m2 on days 1 to 3) was administered. However, the regimen did not produce a response, and the patient died 42 months postoperatively.
The patient developed local recurrence 3 months postoperatively. Thoracic radiotherapy (60 Gy) was performed, but the recurrent tumor continued to progress; pleural dissemination developed. Subsequently, high-dose chemotherapy comprising carboplatin (400 mg/m2 on days −7 and −6), etoposide (15 mg/kg on days −7, −6, −5, and −4), and melpharan (90 mg/m2 on days −7 and −6) was performed, followed by auto-PBSCT. This treatment achieved a partial response, and for a time the patient remained stable with maintenance therapy of doxorubicin alone (50 mg/m2). Tumor regrowth was revealed 24 months postoperatively. At this time, high-dose chemotherapy with flutamide (30 mg/m2 on days −7, −6, −5, −4, −3, and −2), melpharan (70 mg/m2 on days −7 and −6), and ATG (2.5 mg/kg on days −5, −4, −3, and −2) was performed, followed by allogeneic peripheral blood stem cell transplantation. Although a partial response was temporarily achieved, the recurrent tumor grew again; the patient died 35 months after the operation.
Comparison of patients with malignant and benign neurogenic tumors
Patient characteristics in the benign and malignant neurogenic tumor groups
BNT ( n = 21)
MNT ( n = 3)
52 ± 18 (15 to 72)a
27 ± 14 (17 to 43)a
33.9 ± 22.8 (11 to 90)a
43 ± 6.1 (30 to 50)a
Intraspinal extension (yes/no)
FDG-PET (positive/negative/not examined)
VATS + Post: 2
VATS → Open: 1
VATS + Post: 1
Alive without Rec: 21
Died of tumor: 3
Three patients with MNT did not receive combined positron emission tomography/computed tomography using the tracer F-18-fluorodeoxyglucose (FDG-PET/CT) before operation. On the other hand, 7 patients out of 21 patients with BNT received FDG-PET/CT before operation. Among them, abnormal FDG uptake was revealed in five patients. Because the sample size was small and we did not have the data of MNT, we could not compare the FDG-PET/CT findings between MNT and BNT.
Neurogenic tumors are generally grouped into two categories: those of nerve sheath origin and those of sympathetic ganglia origin. Nerve sheath tumors are common in adults, while sympathetic ganglia tumors are common in children. Both types have malignant counterparts. Neurogenic tumors represent approximately 30% of all mediastinal neoplasms; most are BNTs, which have a good prognosis after resection . Intrathoracic MNTs are rare, and few studies have described their clinical characteristics or outcomes.
We treated three patients with intrathoracic MNTs: two of nerve sheath origin and one of sympathetic ganglia origin. Although the three lesions were surgically excised, each patient relapsed within 1 year following the initial treatment. The first relapse was systemic in two patients and local in one patient. The patient with local recurrence underwent radiotherapy, which was unsuccessful in stopping the tumor growth. The other two patients received radiotherapy as an adjuvant treatment, but they had distant metastases and ultimately died of their disease. Generally, adjuvant radiotherapy is recommended after MNT resection to improve local control [4-6]. However, there is insufficient evidence regarding the efficacy of radiotherapy for MNT. While some papers have reported effective treatment with radiotherapy [7,8], it did not appear to improve the outcomes in our cases.
All three patients were treated with chemotherapy after recurrence was detected. There is no standard chemotherapeutic regimen for intrathoracic MNT, so the patients underwent chemotherapy based on regimens for neuroblastoma  or other malignant soft tissue tumors [10,11]. In all cases, their responses were insufficient. Subsequently, each patient underwent high-dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT). George et al. previously reported long-term results from high-risk neuroblastoma cases treated with induction chemotherapy and local control measures followed by autologous PBSCT ; these authors concluded that tandem PBSCT could be safely performed in these patients and that it improved long-term survival. Unfortunately, although our patients’ relapsed lesions temporarily regressed after HSCT treatment, all three patients showed disease progression within 1 year of treatment and died of their disease. Previous reports have also demonstrated a poor prognosis with intrathoracic MNT [3,4,13,14]. Although complete resection is a necessary and potentially curative therapeutic modality for intrathoracic MNT, the prognosis following resection was unsatisfactory in our cases. In addition to local control, the establishment of a strategy to control systemic disease is required, as is the case with other high-risk soft tissue sarcomas.
The clinical characteristics of our three patients with intrathoracic MNTs were compared with those of patients with intrathoracic BNTs resected at our institution during the same time period (Table 1). Patients having MNT were younger compared with patients having BNT, although the BNT group also included a young adult patient. Other clinical features, including symptoms, tumor size, and invasiveness of the tumor, did not differ between the groups. Generally, greater tumor size, involvement of adjacent bony structures, and intraspinal extension are known to be signs of a MNT . In the previously reported imaging analysis, size, surface characteristics, and internal heterogeneity of the lesion were reported to have predictive value of malignancy [15,16]. MRI has advantage in evaluating invasiveness to the neighboring organs and internal characteristics of the lesion. On the other hand, CT is superior in describing the tumor surface and vascularity. However, two of the three MNTs in this report were surgically excised without the combined resection of adjacent structures. Interestingly, the tumor with the most aggressive growth was the smallest in size among our three cases when detected. On the other hand, large-sized tumor or tumor with intraspinal extension was included in the BNT group of our study. In our experience with intrathoracic neurogenic tumors, we have not been able to differentiate MNTs from BNTs prior to resection.
Five of seven patients with BNT receiving FDG-PET/CT had abnormal FDG uptake in our study. Because the findings of FDG-PET/CT between MNT and BNT were not compared, we could not lead to the answer about the usefulness of the FDG-PET/CT. In the previous study, Cardona et al. reported the differences of the FDG uptake between BNT and MNT . Although it may be useful to discriminate between MNT and BNT, further analysis is necessary.
We have presented three cases with intrathoracic MNT. Although all three lesions were completely excised, each of the patients developed recurrence and ultimately died of the disease. The clinical differentiation of MNTs from BNTs was difficult before treatment.
Before operation, we obtained general consent from every patient for using their clinical data for some clinical studies. However, the written informed consent for this case report was not obtained from the patients because this report is just retrospective case report without additional invasive examinations or treatments for the study.
- Strollo DC, Rosado-de-Christenson ML, Jett JR. Primary mediastinal tumors: part II. Tumors of the middle and posterior mediastinum. Chest. 1997;112:1344–57.PubMedView ArticleGoogle Scholar
- Shields TW. Benign and malignant neurogenic tumors of the mediastinum in adults. In: Shields TW, LoCicero III J, Ponn RB, editors. General thoracic surgery. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 2313–27.Google Scholar
- Kourea HP, Bilsky MH, Leung DHY, Lewis JJ, Woodruff JM. Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors. Cancer. 1998;82:2191–203.PubMedView ArticleGoogle Scholar
- Aydm GB, Kutluk MT, Yalçin B, Büyükpamukçu M, Kale G, Varan A, et al. Neuroblastoma in Turkish children. J Pediatr Hematol Oncol. 2009;31:471–80.View ArticleGoogle Scholar
- Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19:878–85.PubMedView ArticleGoogle Scholar
- Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, et al. Malignant peripheral nerve sheath tumors. Cancer. 2006;107:1065–74.PubMedView ArticleGoogle Scholar
- Akhavan A, Binesh F, Ghannadi F, Nabavii H. Excellent response of malignant peripheral nerve sheath tumour of retroperitoneum to radiation therapy. BMJ Case Reports. 2012. doi:10.1136/bcr-2012-007266.Google Scholar
- Gillis AM, Sutton E, Dewitt KD, Matthay KK, Weinberg V, Fisch BM, et al. Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. Int J Radiation Oncol Biol Phys. 2007;69:858–64.View ArticleGoogle Scholar
- Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol. 2002;24:613–21.PubMedView ArticleGoogle Scholar
- Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist. 2007;12:1351–60.PubMedView ArticleGoogle Scholar
- Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol. 2011;22:1266–72.PubMedView ArticleGoogle Scholar
- George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24:2891–6.PubMedView ArticleGoogle Scholar
- Kawachi R, Takei H, Furuyashiki G, Koshi-ishi Y, Goya T. A malignant peripheral nerve sheath tumor of the mediastinum in a patient with neurofibromatosis type 1: report of a case. Surg Today. 2008;38:945–7.PubMedView ArticleGoogle Scholar
- Shimoyama T, Yoshida K, Yamato Y, Koike T, Honma K. Long-term survival after removal of a malignant peripheral nerve sheath tumor originating in the anterior mediastinum. Gen Thorac Cardiovasc Surg. 2009;57:310–4.PubMedView ArticleGoogle Scholar
- Zheng Z, Xinming Z, Yanfeng Z, Lei Y, Jing Z, Jingrui D, et al. Evaluation of CT findings for the differentiation of benign from malignant primary retroperitoneal tumors. Chi Med J. 2014;127:114–9.Google Scholar
- Nishino M, Hayakawa K, Minami M, Yamamoto A, Ueda H, Takasu K. Primary retroperitoneal neoplasms: CT and MR imaging findings with anatomic diagnostic clues. Radiographics. 2003;23:45–57.PubMedView ArticleGoogle Scholar
- Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer G, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol. 2003;29:536–41.PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.